ALX Oncology (ALXO) News Today $0.46 -0.02 (-3.17%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.48 +0.02 (+3.95%) As of 05/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALXO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period ALX Oncology (NASDAQ:ALXO) Price Target Lowered to $1.00 at UBS GroupMay 22 at 4:01 AM | americanbankingnews.comALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast EventMay 20, 2025 | globenewswire.comALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025May 13, 2025 | globenewswire.comALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | finance.yahoo.comALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | globenewswire.com3ALXO : What's Next: ALX Oncology Holdings's Earnings PreviewMay 7, 2025 | benzinga.comALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025May 2, 2025 | globenewswire.comALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trialsApril 28, 2025 | finance.yahoo.comALX Oncology's Phase 2 Trials In Head & Neck Cancer Fail To Meet Primary EndpointsApril 27, 2025 | nasdaq.comEvorpacept fails to meet trial endpoints in HNSCCApril 26, 2025 | investing.comALX Oncology reports ASPEN-03, ASPEN-04 trials did not meet primary endpointsApril 26, 2025 | markets.businessinsider.comALX Oncology reports ‘encouraging’ final results from Phase 1 evorpacept trialApril 26, 2025 | markets.businessinsider.comALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin LymphomaApril 25, 2025 | globenewswire.comALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary EndpointsApril 25, 2025 | globenewswire.comALX Oncology receives IND clearance from FDA for ALX2004April 8, 2025 | markets.businessinsider.comALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug ConjugateApril 7, 2025 | markets.businessinsider.comALX Oncology (NASDAQ:ALXO) Price Target Cut to $1.50 by Analysts at Stifel NicolausStifel Nicolaus cut their price objective on ALX Oncology from $3.00 to $1.50 and set a "hold" rating for the company in a research note on Friday.March 8, 2025 | marketbeat.comALX Oncology files $364.12M mixed securities shelfMarch 8, 2025 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for ALX Oncology (NASDAQ:ALXO)HC Wainwright reiterated a "buy" rating and issued a $5.00 target price on shares of ALX Oncology in a research note on Friday.March 8, 2025 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by BrokeragesShares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation andMarch 8, 2025 | marketbeat.comALX Oncology Holdings Insider Trading Activity | NASDAQ:ALXO | BenzingaMarch 7, 2025 | benzinga.comALX Oncology (NASDAQ:ALXO) Announces Quarterly Earnings Results, Beats Estimates By $0.17 EPSALX Oncology (NASDAQ:ALXO - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.17.March 7, 2025 | marketbeat.comALX Oncology (NASDAQ:ALXO) Given New $9.00 Price Target at Piper SandlerPiper Sandler raised their target price on shares of ALX Oncology from $8.00 to $9.00 and gave the stock an "overweight" rating in a report on Thursday.March 7, 2025 | marketbeat.comALX Oncology (NASDAQ:ALXO) Upgraded to "Buy" at Jefferies Financial GroupJefferies Financial Group upgraded shares of ALX Oncology from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $2.00 to $3.00 in a research note on Thursday.March 7, 2025 | marketbeat.comALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 6, 2025 | globenewswire.comBay Area biotech firm once worth more than $4B lays off 30% of staffMarch 6, 2025 | msn.comALX Oncology price target raised to $9 from $8 at Piper SandlerMarch 6, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and Elicio Therapeutics (ELTX)March 6, 2025 | markets.businessinsider.comALX Oncology upgraded to Buy from Hold at JefferiesMarch 6, 2025 | markets.businessinsider.comALX Oncology will highlight progress across its clinical pipelineMarch 5, 2025 | markets.businessinsider.comALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast EventMarch 5, 2025 | globenewswire.comALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025February 27, 2025 | globenewswire.comALX Oncology (ALXO) Projected to Post Earnings on ThursdayALX Oncology (NASDAQ:ALXO) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comALX Oncology to Host Virtual R&D Day on March 5, 2025February 18, 2025 | globenewswire.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has received an average rating of "Moderate Buy" from the six research firms that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recomFebruary 11, 2025 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest UpdateALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) was the recipient of a large drop in short interest in January. As of January 15th, there was short interest totalling 7,600,000 shares, a drop of 9.4% from the December 31st total of 8,390,000 shares. Based on an average daily volume of 984,300 shares, the days-to-cover ratio is presently 7.7 days. Approximately 24.6% of the shares of the stock are sold short.January 31, 2025 | marketbeat.comALX Oncology (NASDAQ:ALXO) Price Target Lowered to $2.20 at UBS GroupUBS Group reduced their price target on ALX Oncology from $4.00 to $2.20 and set a "buy" rating for the company in a research report on Monday.January 27, 2025 | marketbeat.comHC Wainwright Comments on ALX Oncology FY2029 EarningsALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of ALX Oncology in a report issued on Friday, January 24th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of $0.63 per shareJanuary 27, 2025 | marketbeat.comALX Oncology price target lowered to $5 from $25 at H.C. WainwrightJanuary 25, 2025 | markets.businessinsider.comHold Rating for ALX Oncology Amid Mixed ASPEN-06 Study Results and Financial ConcernsJanuary 24, 2025 | markets.businessinsider.comStifel maintains hold on ALX Oncology shares, keeps $3 targetJanuary 24, 2025 | msn.comH.C. Wainwright cuts ALX Oncology target to $5, keeps buy ratingJanuary 24, 2025 | msn.comALX Oncology's (ALXO) Overweight Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of ALX Oncology in a research report on Friday.January 24, 2025 | marketbeat.comALX Oncology (NASDAQ:ALXO) Price Target Cut to $5.00 by Analysts at HC WainwrightHC Wainwright decreased their price target on shares of ALX Oncology from $25.00 to $5.00 and set a "buy" rating on the stock in a research note on Friday.January 24, 2025 | marketbeat.comCantor Fitzgerald Comments on ALX Oncology FY2025 EarningsALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for ALX Oncology in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($2.21) perJanuary 24, 2025 | marketbeat.comEvorpacept shows promise in HER2-positive cancer trialJanuary 23, 2025 | msn.comALX Oncology stock falls 16% amid Phase 2 data updateJanuary 23, 2025 | msn.comBrokers Issue Forecasts for ALX Oncology FY2025 EarningsALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of ALX Oncology in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company willJanuary 23, 2025 | marketbeat.comALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric CancerJanuary 23, 2025 | globenewswire.comALX Oncology appoints Shantharam as CFO, appoints 2 board directorsJanuary 22, 2025 | markets.businessinsider.com Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address ALXO Media Mentions By Week ALXO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALXO News Sentiment▼-0.450.75▲Average Medical News Sentiment ALXO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALXO Articles This Week▼32▲ALXO Articles Average Week Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immunic News Today Zentalis Pharmaceuticals News Today Kyverna Therapeutics News Today Oramed Pharmaceuticals News Today Anixa Biosciences News Today Cellectis News Today Climb Bio News Today Senti Biosciences News Today Galectin Therapeutics News Today Adagene News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALXO) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
